Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.

Johnston LR, Larsen PD, La Flamme AC, Michel JM, Simmonds MB, Harding SA.

Int J Cardiol. 2013 Aug 10;167(3):995-9. doi: 10.1016/j.ijcard.2012.03.080. Epub 2012 Apr 1.

PMID:
22465351
2.

Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.

Alexopoulos D, Xanthopoulou I, Plakomyti TE, Theodoropoulos KC, Mavronasiou E, Damelou A, Hahalis G, Davlouros P.

Am Heart J. 2013 Jan;165(1):73-9. doi: 10.1016/j.ahj.2012.10.008. Epub 2012 Nov 14.

PMID:
23237136
3.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

4.

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.

J Am Coll Cardiol. 2014 Mar 25;63(11):1061-70. doi: 10.1016/j.jacc.2013.12.023. Epub 2014 Jan 30.

5.

Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.

Migliorini A, Valenti R, Parodi G, Marcucci R, Abbate R, Carrabba N, Gensini GF, Antoniucci D.

Am J Cardiol. 2013 Dec 15;112(12):1843-8. doi: 10.1016/j.amjcard.2013.08.009. Epub 2013 Sep 21.

PMID:
24063827
6.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

7.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators.

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
8.

Switching acute coronary syndrome patients from prasugrel to clopidogrel.

Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.

JACC Cardiovasc Interv. 2013 Feb;6(2):158-65. doi: 10.1016/j.jcin.2012.09.012.

10.

A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.

Bonello L, Laine M, Baumstarck K, Fernandez J, Maillard L, Peyrol M, Bessereau J, Aradi D, Camilleri E, Roubille F, Piot C, Paganelli F, Camoin-Jau L, Dignat-George F.

Int J Cardiol. 2013 Oct 9;168(4):4244-8. doi: 10.1016/j.ijcard.2013.07.147. Epub 2013 Aug 2.

PMID:
23911273
11.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
12.

A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.

Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D.

Thromb Haemost. 2014 Aug;112(2):342-51. doi: 10.1160/TH13-10-0874. Epub 2014 Apr 10.

PMID:
24718389
13.

Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.

Bernlochner I, Mayer K, Morath T, Orban M, Schulz S, Schömig A, Braun S, Kastrati A, Sibbing D.

Thromb Haemost. 2013 Mar;109(3):517-24. doi: 10.1160/TH12-08-0552. Epub 2013 Jan 17.

PMID:
23328965
14.

Factors affecting residual platelet aggregation in prasugrel treated patients.

Alexopoulos D, Xanthopoulou I, Perperis A, Siapika A, Stavrou K, Tsoni E, Davlouros P, Hahalis G.

Curr Pharm Des. 2013;19(28):5121-6.

PMID:
23651444
15.

High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.

Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, O'Connor SA, Bellemain-Appaix A, Barthélémy O, Beygui F, Collet JP, Montalescot G.

Eur Heart J. 2012 May;33(10):1241-9. doi: 10.1093/eurheartj/ehr407. Epub 2011 Nov 7.

PMID:
22067090
16.

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.

Geisler T, Booth J, Tavlaki E, Karathanos A, Müller K, Droppa M, Gawaz M, Yanez-Lopez M, Davidson SJ, Stables RH, Banya W, Zaman A, Flather M, Dalby M.

PLoS One. 2015 Aug 28;10(8):e0135037. doi: 10.1371/journal.pone.0135037. eCollection 2015.

17.

Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity.

Lhermusier T, Voisin S, Mejean S, Garcia C, Sié P, Carrié D.

J Thromb Haemost. 2012 Sep;10(9):1946-9. doi: 10.1111/j.1538-7836.2012.04838.x. No abstract available.

18.

Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.

Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.

Thromb Res. 2013 Jul;132(1):e36-41. doi: 10.1016/j.thromres.2013.05.029. Epub 2013 Jun 19.

PMID:
23791395
19.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
20.

Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.

Cuisset T, Gaborit B, Dubois N, Quilici J, Loosveld M, Beguin S, Loundou AD, Moro PJ, Morange PE, Alessi MC, Dutour A, Bonnet JL.

Int J Cardiol. 2013 Sep 20;168(1):523-8. doi: 10.1016/j.ijcard.2012.09.214. Epub 2012 Oct 16.

PMID:
23084816

Supplemental Content

Support Center